These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2566915)

  • 1. Early dopamine agonist therapy in Parkinson's disease.
    Rinne UK
    Mov Disord; 1989; 4 Suppl 1():S86-94. PubMed ID: 2566915
    [No Abstract]   [Full Text] [Related]  

  • 2. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
    Rinne UK
    Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
    [No Abstract]   [Full Text] [Related]  

  • 3. Strategies in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1993; 146():50-3. PubMed ID: 8101417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine agonists as primary treatment in Parkinson's disease.
    Rinne UK
    Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394
    [No Abstract]   [Full Text] [Related]  

  • 5. Dopamine agonists and Parkinson's disease.
    Burton K; Calne DB
    Clin Neurol Neurosurg; 1984; 86(3):172-7. PubMed ID: 6091965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of dopamine agonists in the treatment of Parkinson's disease].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):54-8. PubMed ID: 12378886
    [No Abstract]   [Full Text] [Related]  

  • 7. [Drug therapy of patients with early-stage parkinson's disease].
    Kondo T
    Nihon Rinsho; 2000 Oct; 58(10):2055-60. PubMed ID: 11068446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pergolide and lisuride for Parkinson's disease.
    Lieberman AN; Leibowitz M; Neophytides A; Kupersmith M; Mehl S; Kleinberg D; Serby M; Goldstein M
    Lancet; 1979 Nov; 2(8152):1129-30. PubMed ID: 91856
    [No Abstract]   [Full Text] [Related]  

  • 9. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa.
    Schwarz J; Scheidtmann K; Trenkwalder C
    Eur Neurol; 1997; 37(4):236-8. PubMed ID: 9208264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug therapy of Parkinson disease].
    Dietrichs E
    Tidsskr Nor Laegeforen; 1992 Oct; 112(24):3106-9. PubMed ID: 1471089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Grosset K; Needleman F; Macphee G; Grosset D
    Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation of artistic productivity in Parkinson's disease.
    Walker RH; Warwick R; Cercy SP
    Mov Disord; 2006 Feb; 21(2):285-6. PubMed ID: 16261619
    [No Abstract]   [Full Text] [Related]  

  • 13. Bromocriptine and lisuride in Parkinson's disease.
    Caraceni T; Giovannini P; Parati E; Scigliano G; Grassi MP; Carella F
    Adv Neurol; 1984; 40():531-5. PubMed ID: 6695632
    [No Abstract]   [Full Text] [Related]  

  • 14. Pergolide in the treatment of patients with early and advanced Parkinson's disease.
    Bonuccelli U; Colzi A; Del Dotto P
    Clin Neuropharmacol; 2002; 25(1):1-10. PubMed ID: 11852289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deterioration in parkinsonism with low-dose pergolide.
    Kellett MW; Steiger MJ
    J Neurol; 1999 Apr; 246(4):309-11. PubMed ID: 10367701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antiparkinsonian activity of dopamine agonists and their interaction with central dopamine receptor subtypes.
    Goldstein M; Lieberman AN; Takasugi N; Shimizu Y; Kuga S
    Adv Neurol; 1990; 53():101-6. PubMed ID: 1978511
    [No Abstract]   [Full Text] [Related]  

  • 17. Bromocriptine in Parkinson's disease.
    Ludin HP; Ringwald E; Lörincz P
    Lancet; 1978 Sep; 2(8089):578-9. PubMed ID: 79947
    [No Abstract]   [Full Text] [Related]  

  • 18. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease.
    Stocchi F; Ruggieri S; Vacca L; Olanow CW
    Brain; 2002 Sep; 125(Pt 9):2058-66. PubMed ID: 12183351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group.
    Allain H; Destée A; Petit H; Patay M; Schück S; Bentué-Ferrer D; Le Cavorzin P
    Eur Neurol; 2000; 44(1):22-30. PubMed ID: 10894991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
    Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.